| Year |
Citation |
Score |
| 2023 |
Pilcher W, Thomas BE, Bhasin SS, Jayasinghe RG, Yao L, Gonzalez-Kozlova E, Dasari S, Kim-Schulze S, Rahman A, Patton J, Fiala M, Cheloni G, Kourelis T, Dhodapkar MV, Vij R, ... ... Cho HJ, et al. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. Npj Genomic Medicine. 8: 3. PMID 36702834 DOI: 10.1038/s41525-022-00340-x |
0.398 |
|
| 2022 |
Yao L, Jayasinghe RG, Lee BH, Bhasin SS, Pilcher W, Doxie DB, Gonzalez-Kozlova E, Dasari S, Fiala MA, Pita-Juarez Y, Strausbauch M, Kelly G, Thomas BE, Kumar SK, Cho HJ, et al. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. Cancer Research Communications. 2: 1255-1265. PMID 36969740 DOI: 10.1158/2767-9764.CRC-22-0022 |
0.314 |
|
| 2020 |
Kinahan C, Mangone MA, Scotto L, Visentin M, Marchi E, Cho HJ, O'Connor OA. The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma. Oncotarget. 11: 1576-1589. PMID 32405334 DOI: 10.18632/oncotarget.27516 |
0.745 |
|
| 2020 |
Mei AH, Tung K, Han J, Perumal D, Laganà A, Keats J, Auclair D, Chari A, Jagannath S, Parekh S, Cho HJ. MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21. Oncotarget. 11: 727-739. PMID 32133047 DOI: 10.18632/oncotarget.27488 |
0.512 |
|
| 2020 |
Bhasin M, Thomas BE, Jayasinghe RG, Fernandez N, Bhasin SS, Kourelis T, Dhodapkar MV, Vij R, Kumar SK, Mehr S, Hamilton M, Cho HJ, Auclair D, Gnjatic S, Ding L, et al. Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study Blood. 136: 6-8. DOI: 10.1182/blood-2020-143350 |
0.373 |
|
| 2020 |
Jayasinghe RG, Yao L, Thomas B, Bhasin SS, Fernandez N, Avigan DE, Kourelis T, Dhodapkar MV, Vij R, Mehr S, Hamilton M, Cho HJ, Auclair D, Gnjatic S, Ding L. Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data Blood. 136: 15-15. DOI: 10.1182/BLOOD-2020-143256 |
0.311 |
|
| 2019 |
Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, Dudley JT, Brody JD, Jagannath S, Greenbaum B, Gnjatic S, et al. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31857430 DOI: 10.1158/1078-0432.Ccr-19-2309 |
0.329 |
|
| 2019 |
Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park AJ, Venhaus RR, Alpaugh RK, Gnjatic S, ... Cho HJ, et al. Autologous lymphocyte infusion supports tumor antigen vaccine-induced immunity in autologous stem cell transplant for multiple myeloma. Cancer Immunology Research. PMID 30745365 DOI: 10.1158/2326-6066.CIR-18-0198 |
0.323 |
|
| 2019 |
Lagana A, Bhalla S, Aleman A, Mei AH, Leshchenko V, Landesman Y, Melnekoff D, Beno I, Madduri D, Richter JR, Chari A, Cho HJ, Jagannath S, Dudley J, Parekh S. A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma Blood. 134: 3101-3101. DOI: 10.1182/Blood-2019-130753 |
0.42 |
|
| 2019 |
Cho HJ, Huo-Chang Mei A, Tung K, Han J, Perumal D, Keats J, Auclair D, Chari A, Jagannath S, Lagana A. MAGE-A3 mediates survival and proliferation through regulation of BIM and p21Cip1 in multiple myeloma Clinical Lymphoma Myeloma and Leukemia. 19: e127. DOI: 10.1016/j.clml.2019.09.210 |
0.336 |
|
| 2018 |
Cho HJ, Mei AH, Tung K, Han J, Perumal D, Keats JJ, Auclair D, Chari A, Jagannath S, Parekh S, Lagana A. MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1 Blood. 132: 4464-4464. DOI: 10.1182/BLOOD-2018-99-118692 |
0.48 |
|
| 2018 |
Lagana A, Ruan DF, Melnekoff D, Leshchenko V, Perumal D, Rahman A, Kim-Schultze S, Song Y, Keats JJ, Yesil J, Auclair D, Madduri D, Richter J, Chari A, Cho HJ, et al. Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma Blood. 132: 59-59. DOI: 10.1182/Blood-2018-99-116828 |
0.329 |
|
| 2018 |
Lagana A, Park S, Edwards D, Leshchenko V, Crochiere M, Landesman Y, Melnekoff D, Beno I, Perumal D, Madduri D, Richter J, Chari A, Cho HJ, Barlogie B, Jagannath S, et al. E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients Blood. 132: 3216-3216. DOI: 10.1182/Blood-2018-99-116500 |
0.366 |
|
| 2017 |
Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Advances. 1: 1575-1583. PMID 29296798 DOI: 10.1200/Jco.2015.33.15_Suppl.8528 |
0.414 |
|
| 2017 |
Melnekoff D, Lagana A, Hamou W, Allette K, Beno I, Leshchenko V, Perumal D, Madduri D, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley J, Sebra R, Parekh S. Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine Blood. 130: 62-62. DOI: 10.1182/Blood.V130.Suppl_1.62.62 |
0.387 |
|
| 2017 |
Cho HJ, Mei AH, Fukui J, Tung K, Perumal D, Leshchenko V, Lagana A, Kim-Schultze S, Chari A, Jagannath S, Parekh S. MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA Blood. 130: 4332-4332. DOI: 10.1182/Blood.V130.Suppl_1.4332.4332 |
0.429 |
|
| 2017 |
Osman K, Chari A, Parekh S, Aleman A, Caro J, Morgan G, Florendo E, Chan E, Strumolo G, Zarychta K, La L, Mandeli J, Kim-Schultze S, Gnjatic S, Jagannath S, ... Cho HJ, et al. Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma Blood. 130: 3282-3282. DOI: 10.1182/Blood.V130.Suppl_1.3282.3282 |
0.359 |
|
| 2017 |
Lagana A, Leshchenko V, Melnekoff D, Beno I, Perumal D, Keats J, DeRome M, Yesil J, Auclair D, Madduri D, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley J, et al. Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma Blood. 130: 268-268. DOI: 10.1182/Blood.V130.Suppl_1.268.268 |
0.385 |
|
| 2016 |
Newman JA, Cooper CD, Roos AK, Aitkenhead H, Oppermann UC, Cho HJ, Osman R, Gileadi O. Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding. Plos One. 11: e0148762. PMID 26910052 DOI: 10.1371/Journal.Pone.0148762 |
0.348 |
|
| 2016 |
Perumal D, Kuo PY, Leshchenko VV, Jiang Z, Divakar SK, Cho HJ, Chari A, Brody J, Reddy MV, Zhang W, Reddy EP, Jagannath S, Parekh S. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research. PMID 26873845 DOI: 10.1158/0008-5472.Can-15-2934 |
0.414 |
|
| 2016 |
Perumal D, Lagana' A, Melnekoff D, Readhead B, Kidd B, Leshchenko VV, Kuo P, Yesil J, Derome M, Auclair D, Madduri D, Chari A, Cho HJ, Barlogie B, Jagannath S, et al. Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma Blood. 128: 802-802. DOI: 10.1182/Blood.V128.22.802.802 |
0.393 |
|
| 2016 |
Cho HJ, Mei A, Fukui J, Tung K, Leshchenko VV, Lagana A, Patel M, Kim-Schulze S, Perumal D, Chari A, Jagannath S, Parekh S. MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins Blood. 128: 3277-3277. DOI: 10.1182/BLOOD.V128.22.3277.3277 |
0.529 |
|
| 2016 |
Osman R, Cho HJ, Mei AH, Newman JA, Gileadi O. Conformational Plasticity of the MAGE-A3 Protein as a Therapeutic Strategy in Multiple Myeloma Biophysical Journal. 110: 5-5. DOI: 10.1016/J.Bpj.2015.11.2862 |
0.446 |
|
| 2015 |
Perumal D, Lagana' A, Rubinsteyn A, Finnigan JP, Kuo P, Leshchenko VV, Chari A, Cho HJ, Jagannath S, Dudley J, Hammerbacher J, Schadt E, Bhardwaj N, Parekh S. Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma Blood. 126: 1851-1851. DOI: 10.1182/Blood.V126.23.1851.1851 |
0.315 |
|
| 2015 |
Gnjatic S, Nataraj S, Imai N, Jungbluth AA, Pan L, Venhaus R, Fellague-Chebra R, Gruselle O, Cohen A, Lendvai N, Cho HJ. Abstract LB-116: Strong MAGE-A3-specific humoral and cellular immune responses in multiple myeloma patients receiving MAGE-A3 protein immunotherapy and peripheral blood lymphocyte reconstitution Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-116 |
0.41 |
|
| 2015 |
Lendvai N, Cohen A, Gnjatic S, Jungbluth A, Bertolini S, Pan L, Venhaus R, Tsakos I, Garcia K, Thibodeau L, Alpaugh K, Cummings N, Lehmann F, Gruselle O, Cho H. Recombinant MAGE-A3 protein immunotherapy and peripheral blood lymphocyte (PBL) reconstitution induce strong antigen-specific humoral and cellular immune responses in patients undergoing autologous stem cell transplantation (ASCT) for consolidation of multiple myeloma (MM) Clinical Lymphoma Myeloma and Leukemia. 15: e140-e141. DOI: 10.1016/j.clml.2015.07.340 |
0.32 |
|
| 2014 |
Perumal D, Leshchenko VV, Kuo P, Jiang Z, Readhead B, Eden C, Athaluri Divakar SK, Zhang W, Cho HJ, Chari A, Reddy M, Reddy EP, Dudley J, Jagannath S, Parekh S. Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition Blood. 124: 3445-3445. DOI: 10.1182/Blood.V124.21.3445.3445 |
0.467 |
|
| 2014 |
Cohen AD, Lendvai N, Gnjatic S, Jungbluth AA, Bertolini S, Pan L, Venhaus R, Tsakos I, Garcia K, Thibodeau L, Alpaugh K, Cummings N, Fellague-Chebra R, Gruselle O, Cho HJ. Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM) Blood. 124: 1184-1184. DOI: 10.1182/BLOOD.V124.21.1184.1184 |
0.36 |
|
| 2014 |
Perumal D, Thirukonda V, Jiang Z, Leshchenko VV, Kuo P, Shahnaz S, Rubel J, Zhang W, Cho HJ, Reddy MVR, Reddy EP, Parekh S. Abstract 1324: Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 is effective in vitro and in vivo in Multiple Myeloma Cancer Research. 74: 1324-1324. DOI: 10.1158/1538-7445.Am2014-1324 |
0.414 |
|
| 2013 |
Mangone M, Mei AH, Scotto L, Visentin M, Marchi E, Goldman ID, Mitsiades CS, O'Connor OA, Cho HJ. Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response Blood. 122: 4430-4430. DOI: 10.1182/Blood.V122.21.4430.4430 |
0.439 |
|
| 2012 |
Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. Combination strategies to enhance antitumor ADCC Immunotherapy. 4: 511-527. PMID 22642334 DOI: 10.2217/Imt.12.38 |
0.412 |
|
| 2012 |
Cohen AD, Lendvai N, Gnjatic S, Jungbluth AA, Pan LS, Bertolini SV, Venhaus RR, Fellague-Chebra R, Gruselle O, Cho HJ. Pilot study of MAGE-A3 protein vaccination and autologous stem cell transplantation (autoSCT) as consolidation therapy for multiple myeloma (MM). Journal of Clinical Oncology. 30: TPS8111-TPS8111. DOI: 10.1200/JCO.2012.30.15_SUPPL.TPS8111 |
0.333 |
|
| 2011 |
Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, ... ... Cho HJ, et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4309-19. PMID 21565982 DOI: 10.1158/1078-0432.Ccr-10-1820 |
0.765 |
|
| 2011 |
Diefenbach CS, Sabado R, Clark-Garvey S, Cruz C, Vengco I, Rojas CN, Serrano V, Zain JM, Cho HJ, O'Connor OA. PD-1 Is Elevated on the Peripheral Blood T Cell Subsets of Patients with Relapsed/Refractory Hodgkin Lymphoma Compared to Normal Volunteers Blood. 118: 4860-4860. DOI: 10.1182/Blood.V118.21.4860.4860 |
0.329 |
|
| 2011 |
Mangone M, Scotto L, Marchi E, O'Connor OA, Cho HJ. Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression Blood. 118: 1831-1831. DOI: 10.1182/Blood.V118.21.1831.1831 |
0.794 |
|
| 2011 |
Nardiello T, Mei A, Mangone M, Cho HJ. CT7 (MAGE-C1) Promotes Survival and Interacts with STAT1 and PIASy in Multiple Myeloma Cells Blood. 118: 1807-1807. DOI: 10.1182/Blood.V118.21.1807.1807 |
0.681 |
|
| 2011 |
Mangone M, Marchi E, Scotto L, O'Connor OA, Cho HJ. Abstract 4530: Pralatrexate-induced apoptosis in multiple myeloma cells correlates with RFC-1 and DHFR expression Cancer Research. 71: 4530-4530. DOI: 10.1158/1538-7445.Am2011-4530 |
0.798 |
|
| 2010 |
Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immunity. 10: 4. PMID 20108890 |
0.766 |
|
| 2010 |
Nardiello T, Jungbluth AA, Mei A, DiLiberto M, Huang X, Ely SA, Niesvizky R, Coleman M, Pearse RN, Jayabalan D, Old LJ, Chen-Kiang S, Cho HJ. MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells Blood. 116: 785-785. DOI: 10.1182/Blood.V116.21.785.785 |
0.773 |
|
| 2009 |
Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S. CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. Journal of Immunology (Baltimore, Md. : 1950). 182: 1810-7. PMID 19201832 DOI: 10.4049/Jimmunol.0713726 |
0.416 |
|
| 2009 |
Cho HJ, Mei A, Nardiello T, DiLiberto M, Huang X, Amengual JE, Jungbluth A, Ely S, Niesvizky R, Jayabalan DS, Old L, Chen-Kiang S. MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma. Blood. 114: 1795-1795. DOI: 10.1182/Blood.V114.22.1795.1795 |
0.771 |
|
| 2008 |
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 111: 1101-9. PMID 17989313 DOI: 10.1182/Blood-2007-05-090258 |
0.333 |
|
| 2006 |
Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL, Outtz HH, Fortunato S, Altorki N, Ferrera CA, Chua R, Jungbluth AA, Chen YT, Old LJ, Simpson AJ. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immunity. 6: 12. PMID 17137291 |
0.367 |
|
| 2006 |
Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Research. 66: 7661-7. PMID 16885367 DOI: 10.1158/0008-5472.Can-06-1098 |
0.354 |
|
| 2006 |
Baughn LB, Di Liberto M, Wu K, Toogood P, Louie T, Gottschalk R, Niesvizky R, Cho HJ, Ely S, Moore MA, Chen-Kiang S. A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6. Blood. 108: 369-369. DOI: 10.1182/Blood.V108.11.369.369 |
0.478 |
|
| 2006 |
Lendvai N, Gnjatic S, Ritter E, Chen Y, Coughlin C, Vonderheide RH, Niesvizky R, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. Host Immune Responses Against CT Antigens in Multiple Myeloma Patients. Blood. 108: 3492-3492. DOI: 10.1182/Blood.V108.11.3492.3492 |
0.462 |
|
| 2006 |
Cho HJ, Ely S, Austin WR, Niesvizky R, Pearse R, Coleman M, Bhardwaj N, DiLiberto M, Chen-Kiang S, Old LJ, Jungbluth AA. Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease. Blood. 108: 3397-3397. DOI: 10.1182/Blood.V108.11.3397.3397 |
0.63 |
|
| 2005 |
Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Research. 65: 11345-53. PMID 16357141 DOI: 10.1158/0008-5472.Can-05-2159 |
0.376 |
|
| 2005 |
Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 106: 167-74. PMID 15761016 DOI: 10.1182/Blood-2004-12-4931 |
0.517 |
|
| 2005 |
Cho HJ, Caballero O, Jungbluth AA, DiLiberto M, Niesvizky R, Old LJ, Chen-Kiang S. Type I MAGE Proteins: Novel Markers of Proliferation in Multiple Myeloma Progenitor Cells. Blood. 106: 5115-5115. DOI: 10.1182/Blood.V106.11.5115.5115 |
0.559 |
|
| 2005 |
Leonard JP, Furman RR, Cheung YK, Feldman EJ, Cho HJ, Vose JM, Nichols G, Glynn PW, Joyce MA, Ketas J, Ruan J, Carew J, Niesvizky R, LaCasce A, Chadburn A, et al. Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results. Blood. 106: 491-491. DOI: 10.1182/Blood.V106.11.491.491 |
0.343 |
|
| 2005 |
Cho HJ, Farol L, Truong JT, Austin WR, Chen Y, Bhardwaj N, Niesvizky R, Old LJ, Chen-Kiang S. CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients. Blood. 106: 356-356. DOI: 10.1182/Blood.V106.11.356.356 |
0.463 |
|
| 2005 |
Jin DK, Young LM, Vincent L, Gelbshtein U, Pekle K, Lam G, Shido K, Cho HJ, Pearse R, Leonard JP, Chen-Kiang S, Coleman M, Rafii S, Niesvizky R. Multimodular Analysis of Angiogenic Biomarkers in the Primary Treatment of Multiple Myeloma: Correlative Studies of the BiRD Trial. Blood. 106: 3483-3483. DOI: 10.1182/Blood.V106.11.3483.3483 |
0.347 |
|
| 2005 |
Niesvizky R, Ely S, DiLiberto M, Cho HJ, Gelbshtein UY, Jayabalan DS, Aggarwal S, Gabrilove JL, Pearse RN, Pekle K, Zafar F, Goldberg Z, Leonard JP, Wright JJ, Chen-Kiang S, et al. Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM). Blood. 106: 2574-2574. DOI: 10.1182/Blood.V106.11.2574.2574 |
0.405 |
|
| 2004 |
Datta SK, Cho HJ, Takabayashi K, Horner AA, Raz E. Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications. Immunological Reviews. 199: 217-26. PMID 15233737 DOI: 10.1111/J.0105-2896.2004.00149.X |
0.37 |
|
| 2004 |
Goldberg* Z, Ely S, Chen-Kiang S, Chesi M, Bergsagel PL, Pekle* K, Lyons* L, Gelbshtein* U, Pearse R, Harpel J, Cho H, Coleman M, Niesvizky R. Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle. Blood. 104: 1497-1497. DOI: 10.1182/BLOOD.V104.11.1497.1497 |
0.401 |
|
| 2003 |
Cho HJ, Bhardwaj N. Against the self: Dendritic cells versus cancer Apmis. 111: 805-817. PMID 12974782 DOI: 10.1034/J.1600-0463.2003.11107812.X |
0.434 |
|
| 2002 |
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 100: 3426-8. PMID 12384448 DOI: 10.1182/Blood-2002-03-0765 |
0.344 |
|
| Show low-probability matches. |